Jeff E. Knight

CIK: 0001881007

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)6 (50.0%)

Position reduction

Option Exercises (M)3 (25.0%)

Derivative conversions

Awards (A)3 (25.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (2)

ALXO

ALX ONCOLOGY HOLDINGS INC

Officer

CRNX

Crinetics Pharmaceuticals, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (12 total)

ALXO
ALX ONCOLOGY HOLDINGS INC
Apr 16, 2026
Award(A)
Stock option (right to buy)
Direct
800K shares-
CRNX
Crinetics Pharmaceuticals, Inc.
Apr 8, 2026
Exercise(M)
Direct
19.3K shares at avg. $19.64$380K
CRNX
Crinetics Pharmaceuticals, Inc.
Apr 8, 2026
Exercise(M)
Direct
49.5K shares at avg. $23.98$1.2M
CRNX
Crinetics Pharmaceuticals, Inc.
Apr 8, 2026
Exercise(M)
Direct
9.6K shares at avg. $20.02$193K
CRNX
Crinetics Pharmaceuticals, Inc.
Apr 8, 2026
Sale(S)
Direct
85.2K shares at avg. $40.10$3.4M
CRNX
Crinetics Pharmaceuticals, Inc.
Mar 16, 2026
Sale(S)
Direct
6K shares at avg. $37.11$221K
CRNX
Crinetics Pharmaceuticals, Inc.
Mar 16, 2026
Sale(S)
Direct
4K shares at avg. $37.77$150K
CRNX
Crinetics Pharmaceuticals, Inc.
Feb 23, 2026
Award(A)
Direct
34K shares-
CRNX
Crinetics Pharmaceuticals, Inc.
Mar 19, 2025
Sale(S)
Direct
6.8K shares at avg. $34.17$232K
CRNX
Crinetics Pharmaceuticals, Inc.
Mar 19, 2025
Sale(S)
Direct
361 shares at avg. $34.83$13K
CRNX
Crinetics Pharmaceuticals, Inc.
Feb 20, 2025
Award(A)
Direct
43K shares-
CRNX
Crinetics Pharmaceuticals, Inc.
Nov 22, 2024
Sale(S)
Direct
501 shares at avg. $56.52$28K

		Type	Shares	Price		Ownership
Apr 16, 2026	ALXO ALX ONCOLOGY HOLDINGS INC	Award(A) Stock option (right to buy)	800,000	-	-	Direct
Apr 8, 2026	CRNX Crinetics Pharmaceuticals, Inc.	Exercise(M)	19,336	$19.64	$379,759	Direct
Apr 8, 2026	CRNX Crinetics Pharmaceuticals, Inc.	Exercise(M)	49,474	$23.98	$1,186,387	Direct
Apr 8, 2026	CRNX Crinetics Pharmaceuticals, Inc.	Exercise(M)	9,624	$20.02	$192,672	Direct
Apr 8, 2026	CRNX Crinetics Pharmaceuticals, Inc.	Sale(S)	85,163	$40.10	$3,415,036	Direct
Mar 16, 2026	CRNX Crinetics Pharmaceuticals, Inc.	Sale(S)	5,950	$37.11	$220,805	Direct
Mar 16, 2026	CRNX Crinetics Pharmaceuticals, Inc.	Sale(S)	3,961	$37.77	$149,607	Direct
Feb 23, 2026	CRNX Crinetics Pharmaceuticals, Inc.	Award(A)	34,000	-	$0	Direct
Mar 19, 2025	CRNX Crinetics Pharmaceuticals, Inc.	Sale(S)	6,801	$34.17	$232,390	Direct
Mar 19, 2025	CRNX Crinetics Pharmaceuticals, Inc.	Sale(S)	361	$34.83	$12,574	Direct
Feb 20, 2025	CRNX Crinetics Pharmaceuticals, Inc.	Award(A)	43,000	-	-	Direct
Nov 22, 2024	CRNX Crinetics Pharmaceuticals, Inc.	Sale(S)	501	$56.52	$28,317	Direct

1-12 of 12 transactions

About Knight Jeff E.

Knight Jeff E. (SEC CIK 0001881007) files insider reports with the SEC as Chief Dev & Operating Officer of ALX ONCOLOGY HOLDINGS INC (ALXO) and Chief Dev. & Operating Officer of Crinetics Pharmaceuticals, Inc. (CRNX).

Signal8 holds 8 ownership filings by Knight Jeff E. (1 Form 3, 7 Form 4), filed between Nov 26, 2024 and Apr 17, 2026. Those filings report 12 transactions, from Nov 22, 2024 to Apr 16, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Knight Jeff E.'s filings is in SAN DIEGO, CA.

Recent filings by Knight Jeff E.

Apr 16, 2026: Grant or award of ALXO derivative securities (Form 4, code A).
Apr 8, 2026: Option exercises of CRNX shares (3 lines, Form 4, code M).
Apr 8, 2026: Open-market sale of CRNX shares (Form 4, code S).
Mar 16, 2026: Open-market sales of CRNX shares (2 lines, Form 4, code S).
Feb 23, 2026: Grant or award of CRNX shares (Form 4, code A).

Other insiders filing for ALX ONCOLOGY HOLDINGS INC (ALXO)

Lettmann Jason, CHIEF EXECUTIVE OFFICER
Wong Shelly, SVP, FINANCE AND CAO
Klencke Barbara, Chief Medical Officer
GOODMAN COREY S, Director
Shantharam Harish, Chief Financial Officer
Garland J. Scott, Director

How to read Form 4 transaction codes